The 1st EACR-OECI Joint Training Course: "Molecular PATHOLOGY Approach to Cancer" will be held from the 7th to the 9th March in Amsterdam.
Organised by Professor Antonio Llombart Bosch, chair of OECI Molecular Pathology Working Group, together with the European Association for Cancer Research (EACR), the course offers an exceptional scientific programme which includes lectures by a number of internationally renowned experts (see http://www.eacr.org/mpathcourse/scientific_programme.php, where you can find scientific as well as all practical information).
Participation in the course will be rewarding in more than one way, as it will give our Pathologists and Molecular Biologists the opportunity to create and strengthen their networks of professional relationships. Finally, it will be an opportunity to get in touch with the Molecular Pathology Working Group that will be surveying members’ necessities and recruiting new active members within the WG.
I would like to urge each OECI members to send a representative to the course. It is my pleasure to remind you that OECI decided to award 10 grants of 500 Euros as expense refund to OECI members/associated members participating in the course.
To receive the grant you need to register for the Molecular Pathology Course and then apply at oeci@oeci.eu. and your application will be quickly processed.
I would also like to ask you to forward this information about the Training Course "Molecular PATHOLOGY” to all staff concerned at your institute and in general to whomever you think might be interested in attending.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.